Skye Bioscience Inc. has released a corporate presentation detailing its developments in the field of obesity treatment. The company is working on pioneering the first CB1 antibody, nimacimab, which aims to address the needs of patients who do not respond to or cannot tolerate existing GLP-1 drugs. The presentation highlights the crowded nature of the GLP-1 space, noting issues with safety and adherence. It also discusses the opportunity for nimacimab to offer a combination option for additional weight loss. Skye Bioscience is focused on addressing fundamental drivers of metabolic diseases, such as increasing energy expenditure and targeting adipose tissue to reduce fat mass. You can access the full presentation through the link below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.